Sarah Aubrey 6/22/26 Sarah Aubrey 6/22/26

Maxwell to Present “Peptoids: The Future of Pharmaceutical Peptides”

Maxwell's Scotch McClure will give a presentation "Peptoids: The Future of Pharmaceutical Peptides" at the Drug Discovery Innovation Programme 2026 September 29-30 in Switzerland.

Joshua McClure 2/28/22 Joshua McClure 2/28/22

Maxwell Biosciences Awarded “Most Promising” 2022 Life Sciences Company in Texas Competition

Caroline B 2/23/22 Caroline B 2/23/22

New Research Published in ACS Infectious Diseases Examines Impact of Self-Assembly of Antimicrobial Peptoids on ESKAPE Bacterial Pathogens

Guest User 5/18/21 Guest User 5/18/21

Maxwell Biosciences Announces the CLAROMER® Brand Biotech Therapeutics Platform as It Advances Toward Clinical Trials

Guest User 4/7/21 Guest User 4/7/21

David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs

Guest User 4/5/21 Guest User 4/5/21

New research published in Pharmaceuticals (MDPI) demonstrates that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2

Guest User 3/10/21 Guest User 3/10/21

MEDIA ADVISORY:Maxwell Biosciences to Present at the Upcoming 2021 Spring Private Company Showcase Hosted by Credit Suisse, Solebury Trout, and Cooley

Guest User 3/3/21 Guest User 3/3/21

Maxwell Biosciences Appoints Kent Kirshenbaum, Ph.D. as Chief Scientific Officer and Sheetal Vali, Ph.D. as Director of Drug Development

Joshua McClure 6/11/19 Joshua McClure 6/11/19

Maxwell Focus: Next Generation Anti-infectives

Maxwell to Present “Peptoids: The Future of Pharmaceutical Peptides”

Maxwell Biosciences Awarded “Most Promising” 2022 Life Sciences Company in Texas Competition

New Research Published in ACS Infectious Diseases Examines Impact of Self-Assembly of Antimicrobial Peptoids on ESKAPE Bacterial Pathogens

Maxwell Biosciences Announces the CLAROMER® Brand Biotech Therapeutics Platform as It Advances Toward Clinical Trials

David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs

New research published in Pharmaceuticals (MDPI) demonstrates that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2

MEDIA ADVISORY:Maxwell Biosciences to Present at the Upcoming 2021 Spring Private Company Showcase Hosted by Credit Suisse, Solebury Trout, and Cooley

Maxwell Biosciences Appoints Kent Kirshenbaum, Ph.D. as Chief Scientific Officer and Sheetal Vali, Ph.D. as Director of Drug Development

Maxwell Focus: Next Generation Anti-infectives

Maxwell Biosciences, Inc.

Company

News

Science